Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T therapy to Europe, the work still to be done to get this product to more patients who need it across the continent, and the future of cell and gene therapy in Europe, with Novartis as a key player driving an emergent field forward.
It is really important to step back and recognise the wonder of it all. We have come so far and should not forget how amazing it is that we are now able to genetically engineer patient cells, put them back into the patient, remove cancers for a long time, and give these patients a new lease of life
